Vivos Therapeutics (VVOS) Capital Expenditures Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.14 Bn | 173.84 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.35 Bn | 125.47 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 107.95 Bn | 98.73 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.16 Bn | 66.71 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 47.67 Bn | 44.00 Bn | 1.29 Bn | 1.81% |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 7.57% |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn | 0.84% |
| 8 | Smith & Nephew | 26.83 Bn | 26.25 Bn | - | - |
| 9 | Koninklijke Philips | 25.36 Bn | 22.23 Bn | 2.07 Bn | 2.15% |
| 10 | Vivos Therapeutics | 6.01 Mn | 3.90 Mn | 3.06 Mn | -28.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.86% |
| Dec 31, 2025 | 179.67% |
| Sep 30, 2025 | -41.45% |
| Jun 30, 2025 | 15.22% |
| Mar 31, 2025 | 0.55% |
| Dec 31, 2024 | -24.41% |
| Sep 30, 2024 | -24.21% |
| Jun 30, 2024 | -64.23% |
| Mar 31, 2024 | -16.78% |
| Dec 31, 2023 | 99.39% |
| Sep 30, 2023 | -236.65% |
| Jun 30, 2023 | 281.72% |
| Mar 31, 2023 | 112.59% |